Figure 4.

Tumor growth response and survival curves for the 14R091 epithelioid mesothelioma patient-derived xenograft (PDX) model. (A) Tumor growth curve of mice treated with ABBV-322 and the ADC control at the doses specified (n = 5 mice in each group). (B) Average tumor volumes from mice at 27 days after treatments were initiated. There was a statistically significant tumor growth inhibition in the ABBV-322 treatment arm on day 27 post-therapy (p = 0.0159, two-sided) compared to the ADC-pyrrolobenzodiazepine (PBD) control arm. The average tumor volumes were 183 mm³ (ADC control) and 96 mm³ (ABBV-322).